Event/Welcome
Opening presentation / Welcome speech
Xosé Bustelo
CHAIR: Xosé Bustelo
SESSION 1
Mechanistic insights into resistance and therapeutic opportunities
Piro Lito
Memorial Sloan Kettering Cancer Center, New York, USA
SESSION 1
A reference map of the ERK interactome
Georg Vucak
Max Perutz Labs, University of Vienna, Vienna BioCenter, Vienna, Austria
SESSION 1
Developing combinatorial therapies for RAS pathway driven cancers
Karen Cichowski
Brigham & Women’s Hospital, Harvard Medical School, Boston, USA
SESSION 1
How SHP2 Signals to RAS
Short talk selected from abstracts
Benjamin neel
NYU Grossman School of Medicine, New York, USA
COFFEE BREAK
CHAIR: Matthias Drosten
SESSION 2
Resistance mechanisms to RAS inhibitor treatment in pancreatic cancer
Christine Sers
Charité, Berlin, Germany
SESSION 2
KRAS mutant isoform-specific vulnerabilities in non-small-cell lung cancer
Angeliki Malliri
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
SESSION 2
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Driven Melanoma
MARTIN McMAHON
Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
SESSION 2
KRAS blockade elicits a DNA damage repair deficiency exploitable with PARP inhibitors.
Short talk selected from abstracts
Gabriela Novoa
CIMA
LUNCH & POSTER SESSION
CHAIR: Esther Castellano
SESSION 3
Oncogenic RAS activity is associated with immune priming in lung adenocarcinoma
Sophie de Carné
Institut Gustave Roussy, Villejuif, France
SESSION 3
Targeting RAS in pancreatic cancer
Andy Aguirre
Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
SESSION 3
Mechanisms of tissue tropism for oncogenic K-RAS
Kevin Haigis
Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
SESSION 3
Isoform-specific regulation of KRAS signaling and lysosomal function by RAP1GDS1-607 in lung adenocarcinoma.
Short talk selected from abstracts
Marta román
University of California, San Francisco, USA
COFFEE BREAK
SESSION 4: Building a Collaborative
European Strategy on RAS (Round table)
SESSION 4
Round table
Moderator – Javier Carmona
VHIO, Barcelona, Spain
René Bernards
NKI, Amsterdam, The Netherlands
Alberto Bardelli
Scientific Director, IFOM, The AIRC Institute of Molecular Oncology, Milano, Italy
Chiara Ambrogio
University of Turin, Turin, Italy
Silve Vicent
CIMA, Pamplona, Spain
Dwight Nissley
Frederick National Laboratory for Cancer Research (NIH), Frederick, USA
Andy Aguirre
Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
END OF DAY 1
SESSION 5: RAS therapies (Clinical perspective)
CHAIR: Colin Lindsay
SESSION 5
TBD
Jayesh Desai
PETER MAcCALLUM CANCER CENTRE, MELBOURNE, AUSTRALIA
SESSION 5
TBD
Jarushka Naidoo
Beaumont RCSI Cancer Centre, Dublin, Ireland
SESSION 5
3D genomic analysis reveals frequent KRAS mutations in multifocal pancreatic precancers
Laura Wood
John Hopkins University School of Medicine, Baltimore, USA
SESSION 5
The D’s V’s and pan(K)’s: tackling KRASnonG12C driven NSCLC
Jia Luo
Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
SESSION 5
RAS inhibitors combinations including Immunotherapy
Francesco Passiglia
Department of Oncology – University of Turin – San Luigi hospital , Orbassano (TO) – Italy
COFFEE BREAK
SESSION 6: Emerging treatments (Preclinical perspective)
CHAIR: David Santamaría
SESSION 6
Targeting K-Ras Using Mutant Selective Covalent Chemistry
Kevan Shokat
University of California, San Francisco, USA
SESSION 6
Targeting KRAS Using PROTAC Degraders
Kirsten Mcaulay
University of Dundee, Dundee, UK
SESSION 6
Allosteric nanobodies to study the interactions between SOS1 and RAS
Jan Steyaert
VIB-VUB Center for Structural Biology, VIB & Vrije Universiteit Brussel, Brussels, Belgium
SESSION 6
VS-7375 (GFH375): An oral, selective KRAS G12D dual ON/OFF inhibitor with superior anti-tumor efficacy relative to ON-only KRAS inhibitors
Short talk selected from abstracts
Jonathan Pachter
Verastem Oncology, US
LUNCH & POSTER SESSION
SESSION 7: Treatments to come (Industry perspective)
CHAIR: Chiara Ambrogio
SESSION 7
Targeting the Oncogenic State of RAS with Tri-Complex Inhibitors
Jan Smith
Revolution medicines, USA
SESSION 7
Blocking effector binding to optimize inhibition of RAS-driven MAPK and AKT signaling in cancer
Pedro Beltrán
BridgeBio Oncology Therapeutics
SESSION 7
Advancing Mutant KRAS Cancer Treatment with Rational Combinations
Carla Martins
AstraZeneca, UK
SESSION 7
Targeting KRAS and the emergence of resistance
Mark Pearson
Boehringer Ingelheim, Germany
Targeting RAS poster awards
courtesy of 
COFFEE BREAK
SESSION 8: Treatments & combinations to come
(Round table)
SESSION 8
Moderator – Colin Lindsay
University of Manchester and the Christie NHS Foundation Trust, Manchester, UK
Ernest Nadal
Catalan Institute of Oncology, L’Hospitalet, Spain
Jia Luo
Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA
Kevan Shokat
University of California, San Francisco, USA
Jayesh Desai
Terri Coneran
KRAS Kickers, USA
END OF DAY 2
Place: Cvm Lavde
MEETING DINNER | Cocktail dinner
CHAIR: Miriam Molina-Arcas
SESSION 9
Targeting the interplay between oncogenic RAS signaling and tumour immune evasion in lung cancer
Julian Downward
Francis Crick Institute, London, UK
SESSION 9
Unmasking contextual determinants of KRAS-driven pancreatic tumorigenesis
Direna Alonso
IRB, Barcelona, Spain
SESSION 9
From Stroma to Strategy: Uncovering Liabilities in CAF–ECM–Tumor Crosstalk in KRAS-Driven Lung Tumors
Esther Castellano
IBMCC-CIC, Salamanca, Spain
SESSION 9
Targeting hyaluronic acid in pancreatic ductal adenocarcinoma uncovers novel therapeutic opportunities
Short talk selected from abstracts
Pian Sun
Spanish National Cancer Research Centre (CNIO), spain
COFFEE BREAK
CHAIR: Silve Vicent
SESSION 10
The EGFR as a Master Regulator of Transcriptional and Metabolic Rewiring in RAS mutant Colorectal Cancer
Maria Sibilia
Medical University of Vienna, Vienna, Austria
SESSION 10
Cell state transitions driving resistance to KRAS inhibition
Tuomas Tammela
Memorial Sloan Kettering Cancer Center, New York, USA
SESSION 10
Oncogene-induced senescence and tumour initiation
Masashi Narita
Cancer Research UK, Cambridge, UK
SESSION 10
RAS GTPases Degradation via LZTR1
Dhirendra Simanshu
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
SESSION 10
Oncogenic KRAS activation induces CRC epithelial plasticity leading to therapeutic resistance in vivo
Short talk selected from abstracts
Andrew Campbell
CRUK Scotland Institute, Scotland
CHAIR: Silve Vicent
SESSION 11
Regulation of MAPK and PI 3′ kinase by RRAS2
FRANK McCORMICK
University of California, San Francisco, USA
END OF DAY 3